Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis)

The purpose of this study was to evaluate the safety and efficacy of excimer laser atherectomy (ELA) with adjunctive percutaneous transluminal angioplasty (PTA) versus PTA alone for treating patients with chronic peripheral artery disease with femoropopliteal bare nitinol in-stent restenosis (ISR)....

Full description

Saved in:
Bibliographic Details
Published inJACC. Cardiovascular interventions Vol. 8; no. 1 Pt A; p. 92
Main Authors Dippel, Eric J, Makam, Prakash, Kovach, Richard, George, Jon C, Patlola, Raghotham, Metzger, D Christopher, Mena-Hurtado, Carlos, Beasley, Robert, Soukas, Peter, Colon-Hernandez, Pedro J, Stark, Matthew A, Walker, Craig
Format Journal Article
LanguageEnglish
Published United States 01.01.2015
Subjects
Online AccessGet full text
ISSN1876-7605
1876-7605
DOI10.1016/j.jcin.2014.09.009

Cover

Abstract The purpose of this study was to evaluate the safety and efficacy of excimer laser atherectomy (ELA) with adjunctive percutaneous transluminal angioplasty (PTA) versus PTA alone for treating patients with chronic peripheral artery disease with femoropopliteal bare nitinol in-stent restenosis (ISR). Femoropopliteal stenting has shown superiority to PTA for lifestyle-limiting claudication and critical limb ischemia, although treating post-stenting artery reobstruction, or ISR, remains challenging. The multicenter, prospective, randomized, controlled EXCITE ISR (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis) trial was conducted across 40 U.S. centers. Patients with Rutherford Class 1 to 4 and lesions of target lesion length ≥4 cm, vessel diameter 5 to 7 mm were enrolled and randomly divided into ELA + PTA and PTA groups by a 2:1 ratio. The primary efficacy endpoint was target lesion revascularization (TLR) at 6-month follow up. The primary safety endpoint was major adverse event (death, amputation, or TLR) at 30 days post-procedure. Study enrollment was stopped at 250 patients due to early efficacy demonstrated at a prospectively-specified interim analysis. A total of 169 ELA + PTA subjects (62.7% male; mean age 68.5 ± 9.8 years) and 81 PTA patients (61.7% male; mean age 67.8 ± 10.3 years) were enrolled. Mean lesion length was 19.6 ± 12.0 cm versus 19.3 ± 11.9 cm, and 30.5% versus 36.8% of patients exhibited total occlusion. ELA + PTA subjects demonstrated superior procedural success (93.5% vs. 82.7%; p = 0.01) with significantly fewer procedural complications. ELA + PTA and PTA subject 6-month freedom from TLR was 73.5% versus 51.8% (p < 0.005), and 30-day major adverse event rates were 5.8% versus 20.5% (p < 0.001), respectively. ELA + PTA was associated with a 52% reduction in TLR (hazard ratio: 0.48; 95% confidence interval: 0.31 to 0.74). The EXCITE ISR trial is the first large, prospective, randomized study to demonstrate superiority of ELA + PTA versus PTA alone for treating femoropopliteal ISR. (Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis [EXCITE ISR]; NCT01330628).
AbstractList The purpose of this study was to evaluate the safety and efficacy of excimer laser atherectomy (ELA) with adjunctive percutaneous transluminal angioplasty (PTA) versus PTA alone for treating patients with chronic peripheral artery disease with femoropopliteal bare nitinol in-stent restenosis (ISR). Femoropopliteal stenting has shown superiority to PTA for lifestyle-limiting claudication and critical limb ischemia, although treating post-stenting artery reobstruction, or ISR, remains challenging. The multicenter, prospective, randomized, controlled EXCITE ISR (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis) trial was conducted across 40 U.S. centers. Patients with Rutherford Class 1 to 4 and lesions of target lesion length ≥4 cm, vessel diameter 5 to 7 mm were enrolled and randomly divided into ELA + PTA and PTA groups by a 2:1 ratio. The primary efficacy endpoint was target lesion revascularization (TLR) at 6-month follow up. The primary safety endpoint was major adverse event (death, amputation, or TLR) at 30 days post-procedure. Study enrollment was stopped at 250 patients due to early efficacy demonstrated at a prospectively-specified interim analysis. A total of 169 ELA + PTA subjects (62.7% male; mean age 68.5 ± 9.8 years) and 81 PTA patients (61.7% male; mean age 67.8 ± 10.3 years) were enrolled. Mean lesion length was 19.6 ± 12.0 cm versus 19.3 ± 11.9 cm, and 30.5% versus 36.8% of patients exhibited total occlusion. ELA + PTA subjects demonstrated superior procedural success (93.5% vs. 82.7%; p = 0.01) with significantly fewer procedural complications. ELA + PTA and PTA subject 6-month freedom from TLR was 73.5% versus 51.8% (p < 0.005), and 30-day major adverse event rates were 5.8% versus 20.5% (p < 0.001), respectively. ELA + PTA was associated with a 52% reduction in TLR (hazard ratio: 0.48; 95% confidence interval: 0.31 to 0.74). The EXCITE ISR trial is the first large, prospective, randomized study to demonstrate superiority of ELA + PTA versus PTA alone for treating femoropopliteal ISR. (Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis [EXCITE ISR]; NCT01330628).
The purpose of this study was to evaluate the safety and efficacy of excimer laser atherectomy (ELA) with adjunctive percutaneous transluminal angioplasty (PTA) versus PTA alone for treating patients with chronic peripheral artery disease with femoropopliteal bare nitinol in-stent restenosis (ISR).OBJECTIVESThe purpose of this study was to evaluate the safety and efficacy of excimer laser atherectomy (ELA) with adjunctive percutaneous transluminal angioplasty (PTA) versus PTA alone for treating patients with chronic peripheral artery disease with femoropopliteal bare nitinol in-stent restenosis (ISR).Femoropopliteal stenting has shown superiority to PTA for lifestyle-limiting claudication and critical limb ischemia, although treating post-stenting artery reobstruction, or ISR, remains challenging.BACKGROUNDFemoropopliteal stenting has shown superiority to PTA for lifestyle-limiting claudication and critical limb ischemia, although treating post-stenting artery reobstruction, or ISR, remains challenging.The multicenter, prospective, randomized, controlled EXCITE ISR (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis) trial was conducted across 40 U.S. centers. Patients with Rutherford Class 1 to 4 and lesions of target lesion length ≥4 cm, vessel diameter 5 to 7 mm were enrolled and randomly divided into ELA + PTA and PTA groups by a 2:1 ratio. The primary efficacy endpoint was target lesion revascularization (TLR) at 6-month follow up. The primary safety endpoint was major adverse event (death, amputation, or TLR) at 30 days post-procedure.METHODSThe multicenter, prospective, randomized, controlled EXCITE ISR (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis) trial was conducted across 40 U.S. centers. Patients with Rutherford Class 1 to 4 and lesions of target lesion length ≥4 cm, vessel diameter 5 to 7 mm were enrolled and randomly divided into ELA + PTA and PTA groups by a 2:1 ratio. The primary efficacy endpoint was target lesion revascularization (TLR) at 6-month follow up. The primary safety endpoint was major adverse event (death, amputation, or TLR) at 30 days post-procedure.Study enrollment was stopped at 250 patients due to early efficacy demonstrated at a prospectively-specified interim analysis. A total of 169 ELA + PTA subjects (62.7% male; mean age 68.5 ± 9.8 years) and 81 PTA patients (61.7% male; mean age 67.8 ± 10.3 years) were enrolled. Mean lesion length was 19.6 ± 12.0 cm versus 19.3 ± 11.9 cm, and 30.5% versus 36.8% of patients exhibited total occlusion. ELA + PTA subjects demonstrated superior procedural success (93.5% vs. 82.7%; p = 0.01) with significantly fewer procedural complications. ELA + PTA and PTA subject 6-month freedom from TLR was 73.5% versus 51.8% (p < 0.005), and 30-day major adverse event rates were 5.8% versus 20.5% (p < 0.001), respectively. ELA + PTA was associated with a 52% reduction in TLR (hazard ratio: 0.48; 95% confidence interval: 0.31 to 0.74).RESULTSStudy enrollment was stopped at 250 patients due to early efficacy demonstrated at a prospectively-specified interim analysis. A total of 169 ELA + PTA subjects (62.7% male; mean age 68.5 ± 9.8 years) and 81 PTA patients (61.7% male; mean age 67.8 ± 10.3 years) were enrolled. Mean lesion length was 19.6 ± 12.0 cm versus 19.3 ± 11.9 cm, and 30.5% versus 36.8% of patients exhibited total occlusion. ELA + PTA subjects demonstrated superior procedural success (93.5% vs. 82.7%; p = 0.01) with significantly fewer procedural complications. ELA + PTA and PTA subject 6-month freedom from TLR was 73.5% versus 51.8% (p < 0.005), and 30-day major adverse event rates were 5.8% versus 20.5% (p < 0.001), respectively. ELA + PTA was associated with a 52% reduction in TLR (hazard ratio: 0.48; 95% confidence interval: 0.31 to 0.74).The EXCITE ISR trial is the first large, prospective, randomized study to demonstrate superiority of ELA + PTA versus PTA alone for treating femoropopliteal ISR. (Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis [EXCITE ISR]; NCT01330628).CONCLUSIONSThe EXCITE ISR trial is the first large, prospective, randomized study to demonstrate superiority of ELA + PTA versus PTA alone for treating femoropopliteal ISR. (Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis [EXCITE ISR]; NCT01330628).
Author Colon-Hernandez, Pedro J
Stark, Matthew A
Patlola, Raghotham
Beasley, Robert
Dippel, Eric J
Makam, Prakash
George, Jon C
Soukas, Peter
Kovach, Richard
Metzger, D Christopher
Mena-Hurtado, Carlos
Walker, Craig
Author_xml – sequence: 1
  givenname: Eric J
  surname: Dippel
  fullname: Dippel, Eric J
  email: dippel@cvmedpc.com
  organization: Genesis Medical Center, Davenport, Iowa. Electronic address: dippel@cvmedpc.com
– sequence: 2
  givenname: Prakash
  surname: Makam
  fullname: Makam, Prakash
  organization: Cardiology Associates of Northwest Indiana, Munster, Indiana
– sequence: 3
  givenname: Richard
  surname: Kovach
  fullname: Kovach, Richard
  organization: Deborah Heart and Lung Center, Browns Mills, New Jersey
– sequence: 4
  givenname: Jon C
  surname: George
  fullname: George, Jon C
  organization: Deborah Heart and Lung Center, Browns Mills, New Jersey
– sequence: 5
  givenname: Raghotham
  surname: Patlola
  fullname: Patlola, Raghotham
  organization: Cardiovascular Clinic of Hattiesburg, Hattiesburg, Mississippi
– sequence: 6
  givenname: D Christopher
  surname: Metzger
  fullname: Metzger, D Christopher
  organization: Wellmont Holston Valley, Kingsport, Tennessee
– sequence: 7
  givenname: Carlos
  surname: Mena-Hurtado
  fullname: Mena-Hurtado, Carlos
  organization: Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
– sequence: 8
  givenname: Robert
  surname: Beasley
  fullname: Beasley, Robert
  organization: Division of Radiology, Mount Sinai Heart Institute, Miami Beach, Florida
– sequence: 9
  givenname: Peter
  surname: Soukas
  fullname: Soukas, Peter
  organization: The Miriam Hospital, Providence, Rhode Island
– sequence: 10
  givenname: Pedro J
  surname: Colon-Hernandez
  fullname: Colon-Hernandez, Pedro J
  organization: Centro Cardiovascular de Puerto Rico y el Caribe, San Juan, Puerto Rico
– sequence: 11
  givenname: Matthew A
  surname: Stark
  fullname: Stark, Matthew A
  organization: The Spectranetics Corporation, Colorado Springs, Colorado
– sequence: 12
  givenname: Craig
  surname: Walker
  fullname: Walker, Craig
  organization: Cardiovascular Institute of the South, Houma, Louisiana
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25499305$$D View this record in MEDLINE/PubMed
BookMark eNpNkUtr4zAUhcXQYfr8A7MoWrYLeyTZkqvuSkjbQKCQeDG7oFoyo6CHK8kwmX_eXeVMH9noXu49nPNxdQqOnHcKgJ8YlRhh9mtbbjvtSoJwXSJeIsS_gRN807CiYYgeHfTH4DTGLUIM8Yb8AMeE1pxXiJ6A15Vw0lv9T0nYeZeCNya3MY1yB30P1d9OWxWgETG_Iv1RQXXJ2x3sfYApKJGscmmS9sr64Ac_GJ2UMFC7IqZpF9RUfdTxNg910nmZZ6NJEfbBW5hd4fz3bNHO4WK9yq6T4mqaTNHLffQB5-yLc73nnFDaQ5T7L5R2nr0WrljvUVafKNfn4HsvTFQX7_UMtPfzdvZYLJ8eFrO7ZTGQuk4F41Rg3kuKJeurppGoYw0XdY1qnLtGVl0jGeckq58pQ30-MiUCK3SDpKTVGbj6bzsE_zLm-I3VsVPGCKf8GDeYUVJXlCCSpZfv0vHZKrkZgrYi7DYfv1W9AbZ8n2s
ContentType Journal Article
Contributor Lee, Arthur
Raja, M Laiq
Luft, Ulrich
Lowry, Richard
Harrison, Lonnie
Venkatesan, Jayaraman
Salvaggio, Louis
Gallino, Robert
Karenko, Barbara
Van Roy, Daniel
Vouyouka, Ageliki
Ingraldi, Agostino
Shimshak, Thomas
Goldstein, Jeffrey
Wilkins, Robert
Chamberlin, Jack
Colleran, John
Sakhuja, Rahul
Mustapha, Jihad
Zughaib, Marcel
Nelson, Brian
Eaves, William
Ramaiah, Venkatesh
Uceda, Pablo
Bose, Rahul
Yoho, Jason
Laird, John
Weatherford, David
Foster, Robert
Mego, David
Mishkel, Gregory
Shammas, Nicolas
Veerina, Kalyan
Stewart, Jeffrey
Mangalmurti, Sarang
O'Meara, James
Asfour, Wail
Panneton, Jean
Wheatley, Grayson
Lookstein, Robert
Jacobs, Donald
Trimm, James
Falcone, Wayne
Bernardo, Nelson
Kollmeyer, Kenneth
Babaev, Anvar
Carr, Jeff
Robken, Jon
Janzer, Sean
Rossbach, Mario
Pratsos, Antonis
Marrero, Edwin Pérez
Bunch, Frank
Gupta, Anjan
Pastor-Cervantes, Juan
Menuet, Robert
Cawich, Ian
Das, Tony
Rodriguez, Julio
Deshmukh, Deepak
Contributor_xml – sequence: 1
  givenname: Jon
  surname: Robken
  fullname: Robken, Jon
– sequence: 2
  givenname: Nicolas
  surname: Shammas
  fullname: Shammas, Nicolas
– sequence: 3
  givenname: Ulrich
  surname: Luft
  fullname: Luft, Ulrich
– sequence: 4
  givenname: Jeffrey
  surname: Goldstein
  fullname: Goldstein, Jeffrey
– sequence: 5
  givenname: Gregory
  surname: Mishkel
  fullname: Mishkel, Gregory
– sequence: 6
  givenname: Jeffrey
  surname: Stewart
  fullname: Stewart, Jeffrey
– sequence: 7
  givenname: David
  surname: Mego
  fullname: Mego, David
– sequence: 8
  givenname: Ian
  surname: Cawich
  fullname: Cawich, Ian
– sequence: 9
  givenname: Lonnie
  surname: Harrison
  fullname: Harrison, Lonnie
– sequence: 10
  givenname: Wail
  surname: Asfour
  fullname: Asfour, Wail
– sequence: 11
  givenname: Agostino
  surname: Ingraldi
  fullname: Ingraldi, Agostino
– sequence: 12
  givenname: Louis
  surname: Salvaggio
  fullname: Salvaggio, Louis
– sequence: 13
  givenname: Brian
  surname: Nelson
  fullname: Nelson, Brian
– sequence: 14
  givenname: Thomas
  surname: Shimshak
  fullname: Shimshak, Thomas
– sequence: 15
  givenname: Rahul
  surname: Sakhuja
  fullname: Sakhuja, Rahul
– sequence: 16
  givenname: Grayson
  surname: Wheatley
  fullname: Wheatley, Grayson
– sequence: 17
  givenname: Julio
  surname: Rodriguez
  fullname: Rodriguez, Julio
– sequence: 18
  givenname: Venkatesh
  surname: Ramaiah
  fullname: Ramaiah, Venkatesh
– sequence: 19
  givenname: Nelson
  surname: Bernardo
  fullname: Bernardo, Nelson
– sequence: 20
  givenname: Kenneth
  surname: Kollmeyer
  fullname: Kollmeyer, Kenneth
– sequence: 21
  givenname: Pablo
  surname: Uceda
  fullname: Uceda, Pablo
– sequence: 22
  givenname: Jack
  surname: Chamberlin
  fullname: Chamberlin, Jack
– sequence: 23
  givenname: Tony
  surname: Das
  fullname: Das, Tony
– sequence: 24
  givenname: Robert
  surname: Foster
  fullname: Foster, Robert
– sequence: 25
  givenname: James
  surname: Trimm
  fullname: Trimm, James
– sequence: 26
  givenname: Robert
  surname: Gallino
  fullname: Gallino, Robert
– sequence: 27
  givenname: John
  surname: Laird
  fullname: Laird, John
– sequence: 28
  givenname: Frank
  surname: Bunch
  fullname: Bunch, Frank
– sequence: 29
  givenname: Anjan
  surname: Gupta
  fullname: Gupta, Anjan
– sequence: 30
  givenname: Jean
  surname: Panneton
  fullname: Panneton, Jean
– sequence: 31
  givenname: Deepak
  surname: Deshmukh
  fullname: Deshmukh, Deepak
– sequence: 32
  givenname: Donald
  surname: Jacobs
  fullname: Jacobs, Donald
– sequence: 33
  givenname: Antonis
  surname: Pratsos
  fullname: Pratsos, Antonis
– sequence: 34
  givenname: Sean
  surname: Janzer
  fullname: Janzer, Sean
– sequence: 35
  givenname: Sarang
  surname: Mangalmurti
  fullname: Mangalmurti, Sarang
– sequence: 36
  givenname: Anvar
  surname: Babaev
  fullname: Babaev, Anvar
– sequence: 37
  givenname: William
  surname: Eaves
  fullname: Eaves, William
– sequence: 38
  givenname: Robert
  surname: Wilkins
  fullname: Wilkins, Robert
– sequence: 39
  givenname: Wayne
  surname: Falcone
  fullname: Falcone, Wayne
– sequence: 40
  givenname: David
  surname: Weatherford
  fullname: Weatherford, David
– sequence: 41
  givenname: Jihad
  surname: Mustapha
  fullname: Mustapha, Jihad
– sequence: 42
  givenname: Barbara
  surname: Karenko
  fullname: Karenko, Barbara
– sequence: 43
  givenname: John
  surname: Colleran
  fullname: Colleran, John
– sequence: 44
  givenname: Edwin Pérez
  surname: Marrero
  fullname: Marrero, Edwin Pérez
– sequence: 45
  givenname: Juan
  surname: Pastor-Cervantes
  fullname: Pastor-Cervantes, Juan
– sequence: 46
  givenname: M Laiq
  surname: Raja
  fullname: Raja, M Laiq
– sequence: 47
  givenname: Marcel
  surname: Zughaib
  fullname: Zughaib, Marcel
– sequence: 48
  givenname: Kalyan
  surname: Veerina
  fullname: Veerina, Kalyan
– sequence: 49
  givenname: Robert
  surname: Menuet
  fullname: Menuet, Robert
– sequence: 50
  givenname: Jayaraman
  surname: Venkatesan
  fullname: Venkatesan, Jayaraman
– sequence: 51
  givenname: Robert
  surname: Lookstein
  fullname: Lookstein, Robert
– sequence: 52
  givenname: Ageliki
  surname: Vouyouka
  fullname: Vouyouka, Ageliki
– sequence: 53
  givenname: Mario
  surname: Rossbach
  fullname: Rossbach, Mario
– sequence: 54
  givenname: Jason
  surname: Yoho
  fullname: Yoho, Jason
– sequence: 55
  givenname: Rahul
  surname: Bose
  fullname: Bose, Rahul
– sequence: 56
  givenname: Jeff
  surname: Carr
  fullname: Carr, Jeff
– sequence: 57
  givenname: Richard
  surname: Lowry
  fullname: Lowry, Richard
– sequence: 58
  givenname: Arthur
  surname: Lee
  fullname: Lee, Arthur
– sequence: 59
  givenname: James
  surname: O'Meara
  fullname: O'Meara, James
– sequence: 60
  givenname: Daniel
  surname: Van Roy
  fullname: Van Roy, Daniel
Copyright Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
CorporateAuthor EXCITE ISR Investigators
CorporateAuthor_xml – name: EXCITE ISR Investigators
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.jcin.2014.09.009
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1876-7605
ExternalDocumentID 25499305
Genre Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
18M
1B1
1P~
1~.
4.4
457
4G.
53G
5GY
5VS
7-5
8P~
AACTN
AAEDT
AAEDW
AAIKJ
AALRI
AAOAW
AAQFI
AAXUO
ABBQC
ABFRF
ABJNI
ABMAC
ABMZM
ABWVN
ABXDB
ACGFO
ACGFS
ACRPL
ADBBV
ADEZE
ADMUD
ADNMO
ADVLN
AEFWE
AEKER
AEVXI
AEXQZ
AFCTW
AFETI
AFJKZ
AFRHN
AFTJW
AGHFR
AGYEJ
AITUG
AJRQY
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BAWUL
BLXMC
CGR
CS3
CUY
CVF
DIK
EBS
ECM
EIF
EJD
F5P
FDB
FEDTE
FNPLU
GBLVA
H13
HVGLF
HZ~
IXB
J1W
M41
MO0
N9A
NPM
O-L
O9-
OAUVE
OA~
OK1
OL0
P-8
P-9
P2P
PC.
Q38
RIG
ROL
SDF
SEL
SES
SSZ
W8F
Z5R
7X8
AAYWO
EFKBS
EFLBG
~HD
ID FETCH-LOGICAL-p244t-695a19fd51d6f377d0c679a44041c677d3c7d6992244b560f06052a1e080dd53
ISSN 1876-7605
IngestDate Sun Sep 28 14:01:52 EDT 2025
Thu Apr 03 07:01:33 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1 Pt A
Keywords percutaneous transluminal angioplasty
excimer laser atherectomy
peripheral artery disease
femoropopliteal artery
in-stent restenosis
randomized controlled trial
Language English
License Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p244t-695a19fd51d6f377d0c679a44041c677d3c7d6992244b560f06052a1e080dd53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
PMID 25499305
PQID 1652435202
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1652435202
pubmed_primary_25499305
PublicationCentury 2000
PublicationDate 2015-01-01
PublicationDateYYYYMMDD 2015-01-01
PublicationDate_xml – month: 01
  year: 2015
  text: 2015-01-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle JACC. Cardiovascular interventions
PublicationTitleAlternate JACC Cardiovasc Interv
PublicationYear 2015
References 25560374 - Nat Rev Cardiol. 2015 Feb;12(2):63
References_xml – reference: 25560374 - Nat Rev Cardiol. 2015 Feb;12(2):63
SSID ssj0060972
Score 2.532264
Snippet The purpose of this study was to evaluate the safety and efficacy of excimer laser atherectomy (ELA) with adjunctive percutaneous transluminal angioplasty...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 92
SubjectTerms Aged
Alloys
Amputation
Angioplasty, Balloon - adverse effects
Angioplasty, Balloon - instrumentation
Angioplasty, Balloon - mortality
Atherectomy - adverse effects
Atherectomy - instrumentation
Atherectomy - methods
Atherectomy - mortality
Chronic Disease
Combined Modality Therapy
Constriction, Pathologic
Female
Femoral Artery - physiopathology
Femoral Artery - surgery
Humans
Laser Therapy - adverse effects
Laser Therapy - instrumentation
Laser Therapy - methods
Laser Therapy - mortality
Lasers, Excimer - adverse effects
Lasers, Excimer - therapeutic use
Limb Salvage
Male
Middle Aged
Peripheral Arterial Disease - diagnosis
Peripheral Arterial Disease - mortality
Peripheral Arterial Disease - surgery
Peripheral Arterial Disease - therapy
Popliteal Artery - physiopathology
Popliteal Artery - surgery
Prospective Studies
Prosthesis Design
Recurrence
Stents
Time Factors
Treatment Outcome
United States
Vascular Patency
Title Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis)
URI https://www.ncbi.nlm.nih.gov/pubmed/25499305
https://www.proquest.com/docview/1652435202
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier)
  customDbUrl:
  eissn: 1876-7605
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0060972
  issn: 1876-7605
  databaseCode: GBLVA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier Free Content
  customDbUrl:
  eissn: 1876-7605
  dateEnd: 20241001
  omitProxy: true
  ssIdentifier: ssj0060972
  issn: 1876-7605
  databaseCode: IXB
  dateStart: 20080201
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection
  customDbUrl:
  eissn: 1876-7605
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0060972
  issn: 1876-7605
  databaseCode: .~1
  dateStart: 20080201
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1876-7605
  dateEnd: 20241001
  omitProxy: true
  ssIdentifier: ssj0060972
  issn: 1876-7605
  databaseCode: DIK
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEF6SFEovpe-mL6ZQSotRsN52b6lrk7R2GmwFfBOSVgKlsaRGMpT88946s7vyqm4KaS9iWcvSwHzaeey3M4y9iThVEHFTw7cH3EB7bRsRLYZW6sfDJHMcLrZiZife0Znzeekud3ahw1paN_FBcnXtuZL_0SrOoV7plOw_aHbzUJzAMeoXr6hhvN5Ix_Oo4OUqv0p5Szm_wGHd1olOfyT5KqWcJErTE64e5ehXkqOpKeZ4a0aE27IqKzqSLOpwGKh-_E207ijKOhfUuZyoRqIVQL2-aGp9OGW8HOEa2DtezHuyDwg6rjRHr5-K13dkHWlZF0JWEifoijPR4gRjUQ3EWAhx5loclcJoHevD0eiA6Cu_sWs7hM5N7PAprypJTSAboLfFZtE3-XGcXuKo3qTJv-DzZL-sThECQVkS2wlqC0Jlm1X-xHQ7-RO55KM9MHyvL_fW02vmlJ0YdD-H3mmjks1y4ZcN_f6wRzI1cn5wnuRUbNeURXX7Q219W8bByddwcjadhsF4GbytvhvUF434A6pJzC67ZfmeRz06jpcfW1_Do-JLlFJo5VXHwiSDcfulfw-ihDMV3GN3VRQEhxLS99lOWjxgt2eK5_GQ_dRoAY1sEMiGMgOFbBDIhg6yAaEEG2TTrVvIhhbZoJH9ARSuQeEaCNeATwWJa0Bcg8A1vFOoBoFq6MipUQ0C1UKUoCvKFqqhRTVoVL9_xILJOBgdGapJiVGhZ9wY3tCNzGHGXZN7me37vJ94_jCispsmjnxuJz73qPqz48QYXmSoNNeKzBRDNc5d-zHbK8oifcogiWKrP_DQgU5iJ47dOIsSDE9w0bQjnvFsn71u1ReiDaCNvahIy3Udmp5rYdhj9a199kTqNaxksZpQJIDQqD-7wb-fszv6C3nB9prLdfoSfe4mfiVg9wu6IeXL
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Randomized+controlled+study+of+excimer+laser+atherectomy+for+treatment+of+femoropopliteal+in-stent+restenosis%3A+initial+results+from+the+EXCITE+ISR+trial+%28EXCImer+Laser+Randomized+Controlled+Study+for+Treatment+of+FemoropopliTEal+In-Stent+Restenosis%29&rft.jtitle=JACC.+Cardiovascular+interventions&rft.au=Dippel%2C+Eric+J&rft.au=Makam%2C+Prakash&rft.au=Kovach%2C+Richard&rft.au=George%2C+Jon+C&rft.date=2015-01-01&rft.issn=1876-7605&rft.eissn=1876-7605&rft.volume=8&rft.issue=1+Pt+A&rft.spage=92&rft_id=info:doi/10.1016%2Fj.jcin.2014.09.009&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1876-7605&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1876-7605&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1876-7605&client=summon